Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase III, randomized, partially blinded, multicenter trial to evaluate the
efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo
plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or
primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based
chemotherapy or 3rd relapse.